Charges, generic Lipitor cut Pfizer 1Q net 19 pct - Yahoo Finance

Generic competition for Pfizer Inc.'s blockbuster cholesterol pill Lipitor is starting to cut into the bottom line of the world's biggest drugmaker, as expected. The best-selling drug in the industry's history saw its U.S. patent expire on Nov ...

Ind-Swift, Wockhardt launch generic Lipitor in UK - Reuters India

REUTERS - Drugmakers Ind-Swift (INSW.NS) and Wockhardt (WCKH.NS) have jointly launched a generic version of Pfizer's (PFE.N) cholesterol lowering drug Lipitor in the United Kingdom, the two companies said. The copycat version was launched on the ...

Generic versions of Lipitor to hit pharmacy shelves - News-Medical.Net

In just days, a number of generic versions of Lipitor will hit pharmacy shelves. Pfizer's 180-day generic exclusivity agreement for the medication expires at the end of the month. That will bring a host of new generic alternatives, and potential ...

Atorvastatin Lifts Ranbaxy While Pfizer Abandons Its Lipitor Marketing Efforts - Forbes

Pfizer will no longer aggressively market Lipitor (atorvastatin), its former crown jewel and the most lucrative pharmaceutical product ever. At the same time, generic drug manufacturer Ranbaxy posted record revenue for the last business quarter ...

Lipitor marketing reaches the end of the road - PRWeek

Pfizer is giving up the ghost when it comes to promoting cholesterol drug Lipitor in the US. The patent on the drug expired November 30 of last year. Pfizer had touted the drug through its "Lipitor for You" program, which provided consumers with a co-pay ...

ED GOLDMAN: Lipitor and more - The Business Journal

Quibbles and Obits — An Associated Press story last Wednesday about the probable causes of painter Thomas Kinkade’s death — alcohol and drugs — might have shown that the venerable news service endorses a belief in the afterlife.

Another one bites the dust: Plavix falls off patent today - FiercePharma

And unlike Pfizer ($PFE), which aggressively plugged its newly off-patent Lipitor, Bristol-Myers Squibb ($BMY) plans to back off Plavix marketing immediately. Bristol-Myers sells Plavix in partnership with Sanofi ($SNY), and both companies have ...

Lipitor copy powers a surge in Ranbaxy sales, profits - FiercePharma

What a difference generic Lipitor can make. Ranbaxy Laboratories' first-quarter earnings soared on its launch of the cholesterol drug copycat, to 12.47 billion rupees--$234.3 million--from 3.04 billion rupees last year. The numbers also beat ...

Goodbye, Lipitor. Pfizer Bids a Farewell - Wall Street Journal

Pfizer Inc. conducted an intriguing experiment in brand marketing this year, aggressively pushing the cholesterol-fighting drug Lipitor in the U.S. even after its patent expired on Nov. 30. But after spending more than $87 million promoting the ...

Treatment Algorithms: Dyslipidemia – Statin monotherapies dominate the market but uncontrolled lipid levels remain an issue - Transworld News

Three months after the Lipitor went off patent in the US, primary care physicians were prescribing generics to 35% of their atorvastatin-treated patients, with some patients being switched from other branded statin Crestor. Brand erosion is likely to ...